ClinVar Miner

Submissions for variant NM_152296.5(ATP1A3):c.2401G>A (p.Asp801Asn)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 17
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Courtagen Diagnostics Laboratory,Courtagen Life Sciences RCV000030749 SCV000236542 pathogenic Alternating hemiplegia of childhood 2 2015-03-09 criteria provided, single submitter clinical testing
Baylor Genetics RCV000030749 SCV000245456 pathogenic Alternating hemiplegia of childhood 2 2015-01-06 criteria provided, single submitter clinical testing This variant has been previously reported as disease-causing and was found twice in our laboratory as a de novo finding in affected individuals. Once in a 10-month-old female with epilepsy, developmental delay, hypotonia. Once in a 28-year-old femle with hemiplegic cerebral palsy, seizures, scoliosis, GI problems, intellectual disability.
Genetic Services Laboratory,University of Chicago RCV000030749 SCV000246631 pathogenic Alternating hemiplegia of childhood 2 2014-10-10 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000413511 SCV000336178 pathogenic not provided 2015-10-05 criteria provided, single submitter clinical testing
GeneDx RCV000413511 SCV000490416 pathogenic not provided 2018-12-03 criteria provided, single submitter clinical testing The D801N variant in the ATP1A3 gene has been reported previously in patients with alternating hemiplegia of childhood (Rosewich et al., 2012; Heinzen et al., 2012; Yang et al., 2014). In all cases in which family studies were performed, the D801N variant was shown to arise de novo. D801N is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The D801N variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. The D801N variant is suggested to affect the activity of the Na+/K+ ATPase pump and the substitution of an Aspartic acid for an Asparagine at position 801 is predicted to prevent the normal binding of potassium ions (Heinzen et al., 2012). We interpret D801N as a pathogenic variant.
Fulgent Genetics,Fulgent Genetics RCV000515424 SCV000611249 pathogenic Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome; Dystonia 12; Alternating hemiplegia of childhood 2 2017-05-18 criteria provided, single submitter clinical testing
Ambry Genetics RCV000624579 SCV000742201 pathogenic Inborn genetic diseases 2017-04-28 criteria provided, single submitter clinical testing
Invitae RCV000644928 SCV000766650 pathogenic Dystonia 12 2019-10-28 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid with asparagine at codon 801 of the ATP1A3 protein (p.Asp801Asn). The aspartic acid residue is moderately conserved and there is a small physicochemical difference between aspartic acid and asparagine. This variant is not present in population databases (ExAC no frequency). This variant has been reported to be de novo in multiple individuals affected with alternating hemiplegia of childhood (PMID: 22842232, 22850527, 23409136, 24842602, 24431296). ClinVar contains an entry for this variant (Variation ID: 37107). Experimental studies have shown that this missense change p.Asp801Asn causes reduced ATPase enzyme activity (PMID: 22842232), loss of potassium binding (PMID: 24631656), reduced forward cycling and dominant negativity (PMID: 25681536), and spontaneous recurrent seizures in mice (PMID: 25523819). Multiple missense substitutions at this codon (p.D801E; p.D801V) have been reported in patients with alternating hemiplegia of childhood (PMID: 24100174, PMID: 26410222). This suggests that the aspartic acid residue is critical for ATP1A3 protein function. For these reasons, this variant has been classified as Pathogenic.
SIB Swiss Institute of Bioinformatics RCV000030749 SCV000803614 pathogenic Alternating hemiplegia of childhood 2 2018-05-31 criteria provided, single submitter curation This variant is interpreted as a Pathogenic, for Alternating hemiplegia of childhood-2, in Autosomal Dominant manner. The following ACMG Tag(s) were applied: PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PS3 => Well-established functional studies show a deleterious effect (PMID:22842232). PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PS4-Moderate => PS4 downgraded in strength to Moderate (PMID:23409136) (PMID:22842232). PS2 => De novo (paternity and maternity confirmed) (PMID:23409136) (PMID:22842232).
Institute of Human Genetics,Klinikum rechts der Isar RCV000030749 SCV001149692 pathogenic Alternating hemiplegia of childhood 2 2018-04-06 criteria provided, single submitter clinical testing
Génétique des Maladies du Développement, Hospices Civils de Lyon RCV000030749 SCV001164123 pathogenic Alternating hemiplegia of childhood 2 2016-08-05 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000413511 SCV001247065 pathogenic not provided 2020-02-01 criteria provided, single submitter clinical testing
Centre for Mendelian Genomics,University Medical Centre Ljubljana RCV000644928 SCV001366737 pathogenic Dystonia 12 2019-01-30 criteria provided, single submitter clinical testing This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PM2,PM5,PP2,PP3.
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego RCV001265551 SCV001443703 pathogenic ATP1A3-Related Disorders 2019-12-28 criteria provided, single submitter clinical testing This variant has been previously reported as a de novo heterozygous change in multiple unrelated individuals with alternating hemiplegia of childhood (PMID: 22850527, 22842232, 23409136). Functional studies indicate that this variant exhibits reduced ATPase activity and phosphorylation in cell culture (PMID: 24631656) and manifests behavioral abnormalities, spontaneous recurrent seizures, and paroxysmal motor abnormalities in mouse models (PMID: 25523819). This variant has been reported in the ClinVar database (Variation ID: 37107). It is absent from the ExAC and gnomAD population databases and thus is presumed to be rare. The c.2440G>A (p.Asp814Asn) variant is predicted by multiple in silico tools to have a deleterious effect on protein function. Analysis of the parental samples was negative for the variant, indicating this variant likely occurred as a de novo event. Based on the available evidence, the c.2440G>A (p.Asp814Asn) variant is classified as Pathogenic.
OMIM RCV000030749 SCV000053410 pathogenic Alternating hemiplegia of childhood 2 2014-01-01 no assertion criteria provided literature only
GeneReviews RCV000030749 SCV000195709 pathogenic Alternating hemiplegia of childhood 2 2014-05-04 no assertion criteria provided literature only
NIHR Bioresource Rare Diseases, University of Cambridge RCV001004008 SCV001162052 likely pathogenic Dystonia; Tetraparesis; Oculogyric crisis no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.